Farmaceutica REMEDIA Balance Sheet Health
Financial Health criteria checks 6/6
Farmaceutica REMEDIA has a total shareholder equity of RON66.9M and total debt of RON0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are RON352.6M and RON285.7M respectively. Farmaceutica REMEDIA's EBIT is RON6.1M making its interest coverage ratio -5.7. It has cash and short-term investments of RON31.5M.
Key information
0%
Debt to equity ratio
RON 0
Debt
| Interest coverage ratio | -5.7x |
| Cash | RON 31.51m |
| Equity | RON 66.89m |
| Total liabilities | RON 285.72m |
| Total assets | RON 352.61m |
Recent financial health updates
No updates
Recent updates
Returns At Farmaceutica REMEDIA (BVB:RMAH) Are On The Way Up
Mar 04
Farmaceutica REMEDIA's (BVB:RMAH) Returns On Capital Are Heading Higher
Mar 07Returns Are Gaining Momentum At Farmaceutica REMEDIA (BVB:RMAH)
Aug 18We Like These Underlying Return On Capital Trends At Farmaceutica REMEDIA (BVB:RMAH)
Mar 23Does Farmaceutica REMEDIA (BVB:RMAH) Deserve A Spot On Your Watchlist?
Feb 16Is There More To The Story Than Farmaceutica REMEDIA's (BVB:RMAH) Earnings Growth?
Jan 15Is Farmaceutica REMEDIA S.A.'s (BVB:RMAH) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 16
Should You Invest In Farmaceutica REMEDIA (BVB:RMAH)?
Nov 18Financial Position Analysis
Short Term Liabilities: RMAH's short term assets (RON307.5M) exceed its short term liabilities (RON280.8M).
Long Term Liabilities: RMAH's short term assets (RON307.5M) exceed its long term liabilities (RON4.9M).
Debt to Equity History and Analysis
Debt Level: RMAH is debt free.
Reducing Debt: RMAH has no debt compared to 5 years ago when its debt to equity ratio was 31.5%.
Debt Coverage: RMAH has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RMAH has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 11:34 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Farmaceutica REMEDIA S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Virgil Livanov | Fairwind Consulting |